|Other Names||Guanylate kinase, GMP kinase, GUK1, GMK|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7070a was selected from the N-term region of human GUK1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Essential for recycling GMP and indirectly, cGMP.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Guanylate kinase catalyzes the transfer of phosphate from adenosine triphosphate (ATP) to guanosine monophosphate (GMP) or dGMP. This enzyme functions in the recovery of cGMP and is, therefore, thought to regulate the supply of guanine nucleotides to signal transduction pathways. The GUK2 and GUK3 isoforms are determined by separate loci. Brady et al. (1996) cloned human and mouse cDNAs of GUK1. They stated that the guanylate kinases are targets for cancer chemotherapy and are inhibited by the antitumor drug 6-thioguanine. They reported that the human gene codes for a protein of 197 amino acids with a mass of 21.7 kD. They found that the 1-kb message was ubiquitously expressed.
Brady, W.A., et al., J. Biol. Chem. 271(28):16734-16740 (1996).Fitzgibbon, J., et al., FEBS Lett. 385(3):185-188 (1996).Savitskii, I.V., Ukr. Biokhim. Zh. 62(2):110-114 (1990).Boritzki, T.J., et al., Biochim. Biophys. Acta 658(1):102-110 (1981).Dallapiccola, B., et al., Ann. Genet. 23(2):83-85 (1980).
If you have any additional inquiries please email technical services at email@example.com.